Neratinib(CAS: 698387-09-6)

Neratinib is a small molecule tyrosine kinase inhibitor with the chemical formula C22H23N5O2. It is known for its ability to block the activity of multiple receptor tyrosine kinases, making it a valuable compound in pharmaceutical research. Neratinib has a molecular weight of 385.44 g/mol and is typically supplied as a white to off-white solid. It is used in the treatment of certain cancers, particularly in oncology, due to its targeted mechanism of action.

Neratinib is primarily used in the treatment of HER2-positive breast cancer, especially in patients who have previously been treated with trastuzumab and pertuzumab. It is also being studied for its potential applications in other cancer types, including non-small cell lung cancer and gastrointestinal cancers. As a pharmaceutical compound, Neratinib is valued for its role in targeted therapy and its ability to inhibit multiple kinases involved in cancer progression.

Neratinib is generally considered safe when used under medical supervision, but it may cause side effects such as diarrhea, nausea, and fatigue. Proper handling and adherence to safety guidelines are essential to minimize risks. It is important to follow recommended protective measures, including wearing gloves and eye protection during handling. Safety standards for Neratinib are established by regulatory bodies to ensure its appropriate use in clinical settings.

Neratinib should be stored in a cool, dry place away from direct light. It is typically kept at a temperature range of 15°C to 25°C (59°F to 77°F) in a sealed, light-resistant container. Proper storage conditions help maintain its stability and effectiveness. Avoid exposure to moisture and ensure the container is tightly closed to prevent degradation of the compound.